tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Thomas Smith, 112 are a BUY (86.15%), 18 are a HOLD (13.85%).
Analyst Thomas Smith, carries an average stock price target met ratio of 40.3% that have a potential upside of 30.2% achieved within 149 days. Previously, Thomas Smith worked at LEERINK.
Thomas Smith’s has documented 241 price targets and ratings displayed on 43 stocks. The coverage was on Healthcare, Industrials, Financial Services, Technology, Consumer Defensive sectors.
Most recent stock forecast was given on CLDX, Celldex Therapeutics at 23-Sep-2026.
Analyst best performing recommendations are on AXLA (AXCELLA HEALTH).
The best stock recommendation documented was for AXLA (AXCELLA HEALTH) at 12/15/2022. The price target of $6 was fulfilled within 1 day with a profit of $4.98 (45.36%) receiving and performance score of 453.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$3
$1.79 (147.93%)
$3
2 years 1 months 2 days ago
(26-Sep-2024)
0/4 (0%)
$2.42 (417.24%)
Hold
$7
2 years 4 months 8 days ago
(20-Jun-2024)
1/3 (33.33%)
$0.45 (6.87%)
57
Sell
$1
$-0.21 (-17.36%)
$1.5
2 years 9 months 11 days ago
(17-Jan-2024)
6/6 (100%)
$-0.02 (-1.96%)
278
Buy
2 years 10 months 10 days ago
(18-Dec-2023)
1/1 (100%)
$32.69 (83.16%)
358
Buy
$9
$7.79 (643.80%)
3 years 5 months 17 days ago
(11-May-2023)
2/4 (50%)
$4.84 (116.35%)
178
Which stock is Thomas Smith most bullish on?
Which stock is Thomas Smith most reserved on?
